Patents Examined by Dale R Miller
  • Patent number: 11510874
    Abstract: A method for making reduction sensitive nano micelles comprising: 1) dissolving taurine in distilled water, and adding sodium hydroxide solution; 2) dissolving acryloyl chloride in dichloromethane, reacting at 25° C.; dissolving lipoic acid in toluene and adding hydroxyethyl methacrylate, reacting at 85° C.; 3) dissolving N-acryloyltaurine and lipoic acid methacryloyloxyethyl ester and reacting at 60˜65° C., dropping the polymer solution into deionized water, adding dithiothreitol and reacting at 25˜30° C. to obtain reduction sensitive nano micelles after freeze-drying. The nano micelles have regular morphology and uniform distribution, and can be used as drug carriers for controlled release.
    Type: Grant
    Filed: December 31, 2020
    Date of Patent: November 29, 2022
    Assignee: JIANGNAN UNIVERSITY
    Inventors: Liping Zhang, Caihua Ni, Xinxin Sang, Gang Shi
  • Patent number: 11484543
    Abstract: The present invention relates to the discovery that mutant KCNJ5 is associated with adrenal diseases and disorders. The invention includes compositions and methods for the diagnosis and treatment of adrenal diseases and disorders, based upon the presence or absence of a KCNJ5 mutation that is associated with an adrenal disease or disorder.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: November 1, 2022
    Assignee: The Rockefeller University
    Inventors: Richard Lifton, Ute Scholl
  • Patent number: 11478492
    Abstract: Disclosed herein are compositions comprising tobramycin or a tobramycin derivative that exhibit improvements in permeation of corneal cells, retention in corneal cells, or both. Such compositions can comprise tobramycin or tobramycin derivative(s) complexed to an agent which facilitates improved permeation of corneal cells, retention in corneal cells, or both. The invention also relates to a process of preparing such compositions.
    Type: Grant
    Filed: November 1, 2021
    Date of Patent: October 25, 2022
    Assignee: Somerset Therapuetics, LLC
    Inventors: Mandar V. Shah, Veerappan Subramanian, Ilango Subramanian, Ojas Prakashbhai Doshi
  • Patent number: 11478491
    Abstract: Disclosed herein are compositions comprising tobramycin or a tobramycin derivative that exhibit improvements in permeation of corneal cells, retention in corneal cells, or both. Such compositions can comprise tobramycin or tobramycin derivative(s) complexed to an agent which facilitates improved permeation of corneal cells, retention in corneal cells, or both. The invention also relates to a process of preparing such compositions.
    Type: Grant
    Filed: November 1, 2021
    Date of Patent: October 25, 2022
    Assignee: Somerset Therapeutics, LLC
    Inventors: Mandar V. Shah, Veerappan Subramanian, Ilango Subramanian, Ojas Prakashbhai Doshi
  • Patent number: 11478495
    Abstract: An AMP-activated protein kinase (AMPK) activating agent comprises 1,2-di-O-galloyl-4,6-O—(S)-hexahydroxydiphenoyl-b-D-glucose (“GHG”) as an active ingredient. The AMPK activating agent can be a GHG-containing composition wherein the GHG is an active ingredient of the composition. The GHG-containing composition can be derived from Kenyan purple tea, whose scientific name is Camellia sinensis, variety name: TRFK306. An effective amount of the GHG can be administered to a cell to activate the AMPK. Drinks, foods, and cosmetics can have the GHG as an active ingredient.
    Type: Grant
    Filed: November 10, 2019
    Date of Patent: October 25, 2022
    Assignee: ORYZA OIL & FAT CHEMICAL CO., LTD.
    Inventors: Toru Takarada, Hiroshi Shimoda, Hiromichi Murai
  • Patent number: 11471445
    Abstract: Pharmaceutical compositions are provided for the treatment, pre-emptive treatment or prevention of acute renal injury.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: October 18, 2022
    Assignee: AKI Therapeutics ApS
    Inventor: Lars Otto Uttenthal
  • Patent number: 11471472
    Abstract: Provided in the present invention is the use of a verbascoside in the preparation of a drug for preventing or treating glomerular podocyte injured renal disease, belonging to the field of medicine. The inventors found that the verbascoside can effectively restore the viability of glomerular podocytes, reduce the abnormal migration ability thereof, protect the cytoskeletons of the podocytes, and restore the expression levels of podocyte injury markers, i.e. nephrin protein and synaptopodin protein, thereby significantly reducing urinary protein. Therefore, the verbascoside can be applied to prepare drugs or healthcare products for preventing or treating diseases associated with glomerular podocyte injury, alone or in combination with other drugs, and to prepare drugs or healthcare products for alleviating damage to podocytes caused by other drugs, thereby providing new treatment means and ideas for diseases caused by glomerular podocyte injury.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: October 18, 2022
    Assignee: SICHUAN MEDCO PHARMACEUTICAL STOCK CO., LTD.
    Inventor: Xiaoqi Zhang
  • Patent number: 11464794
    Abstract: The present invention relates to an alginic oligosaccharic diacid composition comprising a mannuronic diacid of Formula (IV) or a pharmaceutically acceptable salt thereof, wherein n is an integer selected from 1 to 9, m is selected from 0, 1 or 2, m? is selected from 0 or 1, and wherein the total weight of alginic oligosaccharic diacid wherein n=1-5 accounts for more than 60% of the total weight of the composition; the total weight of guluronic acids accounts for less than 50% of the total weight of the composition.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: October 11, 2022
    Assignees: GREEN VALLEY (SHANGHAI) PHARMACEUTICALS CO., LTD., SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Meiyu Geng, Zhenqing Zhang, Yingshen Jin, Zhongping Xiao, Jian Ding
  • Patent number: 11464795
    Abstract: Provided are use of a saponin compound of formula (I) or (II), or a pharmaceutically acceptable salt, prodrug or solvate thereof, in the manufacture of a medicament targeting PD-1. The medicament targeting PD-1 is one which treats a disease by inhibiting PD-1 from binding to a ligand thereof. The disease may be a tumor, an infection caused by a bacterium, a virus or a fungus, or an inflammatory disease.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: October 11, 2022
    Assignees: East China University Of Science And Technology, Yunnan University, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Honglin Li, Weilie Xiao, Lili Zhu, Lina Quan, Qiao Li, Yanyan Diao, Zhenjiang Zhao, Hualiang Jiang
  • Patent number: 11452736
    Abstract: The invention relates to a human milk oligosaccharide (HMO) for use in, a synthetic composition comprising an HMO for use in, and a method for the treatment of, secondary prevention of, and/or induction of tolerance to non-coeliac wheat and/or gluten sensitivity in a human.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: September 27, 2022
    Inventors: Louise Kristine Vigsnæs, Bruce McConnell
  • Patent number: 11446226
    Abstract: The present specification discloses a composition for preventing or improving intrinsic aging comprising, as an active ingredient, any one of paeoniflorin or a salt, isomer, hydrate or solvate thereof; and albiflorin or a salt, isomer, hydrate or solvate thereof. Intrinsic aging is one of the natural phenomena occurring with aging, unlike photoaging caused by UV, which is a type of extrinsic aging. The paeoniflorin or albiflorin of the present disclosure is useful for those who want to delay aging and maintain beauty. Accordingly, the paeoniflorin or a salt, isomer, hydrate or solvate thereof; and the albiflorin or a salt, isomer, hydrate or solvate thereof of the present disclosure have the advantage of being capable of being utilized in various forms such as cosmetics, functional health foods, etc.
    Type: Grant
    Filed: November 22, 2018
    Date of Patent: September 20, 2022
    Assignee: Amorepacific Corporation
    Inventors: Jin Sup Shim, Eun Jung Lee, Nok Hyun Park, Yong Jin Kim
  • Patent number: 11446320
    Abstract: A pharmaceutical composition for treating viral infections, including treatments for treatments for coronavirus infections, such as SARS-CoV-2 infections, and illnesses due to the viral infections, such as COVID-19 is provided herein. Also provided are methods for treating viral infections as well as illnesses due to viral infections, such as COVID-19.
    Type: Grant
    Filed: December 30, 2021
    Date of Patent: September 20, 2022
    Assignee: Feynman Labs, LLC
    Inventors: Carl Johan Freer, Richard Kaszynski, Alessandro Gadotti
  • Patent number: 11419886
    Abstract: The present disclosure relates to methods of treating chronic conditions of the eye, such as dry eye disease and blepharitis, as well as to methods for increasing secretion of meibum. This disclosure also relates to formulations suitable for treating chronic conditions of the eye such as dry eye disease and blepharitis.
    Type: Grant
    Filed: November 23, 2021
    Date of Patent: August 23, 2022
    Assignee: SIGHT SCIENCES, INC.
    Inventors: Paul Badawi, David Y. Badawi
  • Patent number: 11413301
    Abstract: The present invention relates to a composition for preventing and treating a Bruch's membrane dysfunction-associated disease, which includes a sea cucumber extract as an active ingredient, and more particularly, to a composition for preventing and treating a Bruch's membrane dysfunction-associated disease, which includes a sea cucumber extract having effects of regenerating the Bruch's membrane of an eye and improving a transport function. The composition according to the present invention improves the transport function of the Bruch's membrane and promotes the regeneration of the Bruch's membrane, thereby delaying or reversing an eye aging process, and thus has excellent effects on the prevention and treatment of a disease such as age-related macular degeneration (AMD), Sorsby's fundus dystrophy, Malattia Levintanese (ML), Stargardt disease, Best's vitelliform retinal dystrophy and Doyne's honeycomb retinal dystrophy (DHRD), which occurs due to the age-related dysfunction of the Bruch's membrane.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: August 16, 2022
    Assignee: Altregen Co., Ltd.
    Inventors: Yunhee Lee, Ali Hussain, Dae Bong Kim
  • Patent number: 11413305
    Abstract: The present invention relates to a use of agar-derived oligosaccharides for inhibiting the growth of Staphylococcus. More specifically, the present invention provides, as a material for medicine, food, cosmetics and the like, a use of agar-derived agarooligosaccharides, agarobiose or AHG, which have an effect of inhibiting the growth of Staphylococcus or killing the same.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: August 16, 2022
    Assignee: Korea University Research and Business Foundation
    Inventors: Kyoung Heon Kim, Jungwoo Yang, Ju Hwan Song, Sora Yu
  • Patent number: 11406651
    Abstract: The present invention relates to the application of mannuronic diacid oligosaccharide composition in the treatment of vascular dementia.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: August 9, 2022
    Assignees: GREEN VALLEY (SHANGHAI) PHARMACEUTICALS CO., LTD., SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Meiyu Geng, Xianliang Xin, Xiaoguang Du, Zhenqing Zhang, Jian Ding
  • Patent number: 11400038
    Abstract: The antioxidant compositions of various embodiments comprise methyl carboxymethylphenylaminocarboxy propylphosphonate, also known as MCAP, (2R)-3-(3,4-dihydroxyphenyl)-2-{[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}propanoic acid, also known as rosmarinic acid, and 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[?-L-rhamnopyranosyl-(1?6)-?-D-glucopyranosyloxy]-4H-chromen-4-one, also known as rutin wherein the antioxidant composition demonstrate a synergistic effect compared with the MCAP, the rosmarinic acid, or the rutin alone. The methods include treating skin or hair damaged by reactive oxygen species, preventing skin or hair damage, and treating aged skin.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: August 2, 2022
    Assignee: Rodan & Fields, LLC
    Inventors: Olga Dueva-Koganov, Taylor Oswald, Christine Crane, Robert Bianchini
  • Patent number: 11400034
    Abstract: A subject of the invention is a cosmetic composition comprising: —from 30% to 89% by weight of at least one polar oil relative to the total weight of the composition; —from 10% to 45% by weight of at least one C2-C6 aliphatic monoalcohol relative to the total weight of the composition; —from 0.5% to 50% by weight of at least one polyol relative to the total weight of the composition; —at least one hydrophilic active agent, said composition comprising less than 7% by weight of water relative to the total weight of the composition. It also relates to the associated cosmetic process and also the cosmetic use of said composition.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: August 2, 2022
    Assignee: L'OREAL
    Inventors: Valérie Page, Céline Demarcq
  • Patent number: 11389567
    Abstract: A method of producing an injectable gel product is provided, comprising (a) cross-linking a first glycosaminoglycan (GAG) with a first crosslinking agent to produce a gel, wherein the charging ratio of crosslinking agent to disaccharide unit is below 0.15; (b) preparing particles of the gel; (c) mixing the glycosaminoglycan (GAG) gel particles with a second GAG to provide a mixture; (d) cross-linking the mixture with a second crosslinking agent to obtain cross-linking between the GAGs of the second, outer phase, thereby providing a gel having a first, inner phase of the cross-linked GAG gel particles, embedded in a gel of the second GAG outer phase; and (e) preparing injectable particles, each such particle containing a plurality of the cross-linked GAG gel particles of the first, inner phase. An injectable gel product, an aqueous composition, and a pre-filled syringe as also provided.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: July 19, 2022
    Assignee: Galderma Holdings SA
    Inventors: Åke Öhrlund, Morgan Karlsson
  • Patent number: 11384110
    Abstract: The present invention relates to a method of removing residual organic solvent from crystalline oligosaccharides by the use of water vapour as well as the pharmaceutically and nutritionally suitable crystalline oligosaccharides obtained by said method.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: July 12, 2022
    Assignee: GLYCOM A/S
    Inventors: Pierre Chassagne, Martin Matwiejuk, Nikolay Khanzhin, Markus Jondelius Hederos